Evolution and current state of assays for measuring parathyroid hormone

Biochemia Medica

Volumn 20, Issue 2, 2010, Pages 221-228

  Skugor, Mario ^a   Gupta, Manjula ^a   Navaneethan, Sankar D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Immunometric assay; Kidney disease; Parathyroid hormone

Indexed keywords

PARATHYROID HORMONE;

ACCURACY; BONE METABOLISM; EVOLUTION; HORMONE ACTION; HORMONE DETERMINATION; HORMONE METABOLISM; HORMONE RELEASE; HYPOPARATHYROIDISM; KIDNEY FAILURE; PRIMARY HYPERPARATHYROIDISM; RADIOIMMUNOASSAY; REVIEW; STANDARDIZATION;

EID: 77953855047     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/bm.2010.027     Document Type: Review

References (49)

1. Brown EM, Mac Lead RJ. Extracelnlular calcium sensing and extracellular calcium signaling. Physiol Rev 2001;81:139-297.
2. Sela-Brown AM, Naveh Many T, Silver J. Transcriptional and post-translational regulation of PTH gene expression by vitamin D, calcium and phosphate. Miner Electrolyte Metab 1999;25:342-344 (Pubitemid 30099688)
3. Naveh Many T, Nechama M. Regulation of parat hyroid hormonem RNA stability by calcium, phosphate and uremia. Curr Opin Nephrol Hypertens 2007;16:305-310
4. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, Gao P, Cantor T, D'Amour P. Origin of parat hyroid hormone (PTH) fragment detected by intact-PTH assays. Eur J Endocri nol 2002;147;123-131
5. Mayer GP, Keaton JA, Hurst JG, Habener JF. EVect of plasma calcium concentration on the relative proportion of hormone and carboxyl fragments in parathyroid venous afluent. En docrinology 1979;104:1778-1784
6. D'Amour P. Effect of acute and chronic hypercalcemia on parathyroid function and circulating PTH molecular forms. Eur J Endocrinol 2002;146:407-410
7. D'Amour P, Segre G, Roth SJ, Potts JT Jr. Analysis of parathyroid hormone and its fragemtns in rat tissues. Chemical Identification and microscopal localization. J Clin Invest 1979;63:89-98.
8. Freitag J, Martin KJ, Hruska KA, Anderson C, Conrades M, Ladenson J, et al. Impaired parathyroid hormone metabolism in patients with chronic renal failure. N Engl J Med 1978;298:29-32.
9. Berson SA, Yalow RS, Aurbach GD, Potts JT Jr. Immunoassay of bovine and human parathyroid hormone. Proc Natl Acad Sci USA 1963;49:613-617
10. Berson SA, Yalow RS. Parathyroid hormone in plasma and adenomatous hyperparathyroidism, uremia, and bronchogenic carcinoma. Science 1966;154:907-909
11. Arnaud CD, Tsao HS, Littledike T. Radioimmunoassay of human parathyroid hormone in serum. J Clin Invest 1971; 50:21-34.
12. Berson SA, Yalow RS. Immunochemical heterogeneity of parathyroid hormone in plasma. J Clin Endocrinol Metab 1968;28:1037-1047
13. Gao P, D'Amour P. Evolution of the parat hyroid hormone (PTH) assays. Importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab 2005;51:21-29
14. Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, et al. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991;73:516-524
15. Coen G, Mazzaferro S, Ballanti P, Bonucci E, Cinotti GA, Fondi G, et al. Two-site immunoradiometric intactparathyroid hormone assay versus C-terminal parathyroid hormone in predicting osteodystrophic bonelesions in predialysis chronic renal failure. J Lab Clin Med 1993;122:103-109
16. Andress DL, Endres DB, Maloney NA, Kopp JB, Coburn JW, Sherrard DJ. Comparison of parathyroid hormone assays with bone histomorphometry in renal osteodystrophy. J Clin Endocrinol Metab 1986;63:1163-1169
17. Tregear GW, Van Rietschoten J, Greene E, Keutmann HT, Niall HD, Reit B, et al. Bovine parathyroid hormone: minimum chain length of synthetic peptide required for biological activity. Endocrinology 1973;93:1349-1353
18. Martin KJ, Hruska KA, Freitag JJ, Bellorin-Font E, Klahr S, Slatopolsky E. Clinical utility of radioimmunoassays for parathyroid hormone. Miner Electrolyte Metab 1980;3:283-290
19. Martin KJ, Hruska KA, Lewis J, Anderson C, Slatopolsky E. The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular Yltration. J Clin Invest 1977; 60:808-814
20. D'Amour P, Brossard JH, Rousseau L, Nguyen-Ya mamo to L, Nassif E, Lazure C, et al. Structure of non-(1-84)PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005;68:998-1007.
21. Sherrard DJ, Hercz G, Pel Y, Maloney NA, Greenwood C, Manuel A, et al. The spectrum of bone disease in end stage renal failure - an evolving disorder. Kidney Int 1993;43:436-442
22. Wang M, Hercz G, Sherrarrd D, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis 1995; 26:836-844
23. Lepage R, Roy L, Brossard JH, Rousseau L, Dorais C, Lazure C, D'Amour P. A no n-(1-84) circulating parathyroid hormone (PTH) fragment interferes signiYcantly with intact PTH commercial assay measurements in uremic samples. Clin Chem 1998;44:805-809
24. D'Amour P, Brossard JH, Rousseau L, Roy L, Gao P, Cantor T. Amino-terminal form of parat hyroid hormone (PTH) with immunologic similarities to hPTH (1-84) is overproduced in primary and secondary hyperparathyroidism. Clin Chem 2003;49:2037-2044
25. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P. Accumulation of a non-(1-84) molecular form of parat hyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the inter pretation of PTH values. J Clin Endocrinol Metab 1996;81:3923-3929
26. Brossard JH, Lepage R, Cardinal H, Roy L, Rousseau L, Dorais C, et al. Influece of glomerular filtration rate on intact parathyroid hormone levels in renal failure patients: role of non-(1-84) PTH detected by intact PTH assays. Clin Chem 2000;46:697-703.
27. Divieti P, John MR, Juppner H, Bringhurst FR. Human PTH (7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002;143:171-176
28. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderaterenal failure. Endocrinology 2003;144:1135-1138
29. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Jüppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999;84:4287-4290
30. Gao P, Scheibel S, D'Amour P, John MR, Rao DS, Schmidt, Gayk H, Cantor TL. Development of a novel immunoradiometric assay exclusively for biologically active whole parat hyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001;16:605-614
31. Slatopolsky E, Finch J, Caly P, Martin D, Sicard G, Singer G, et al. A novel mechanism for skeletal resistance in uremia. Kindney Int 2000;58:753-761
32. Monier-Faugere MC, Geng Z, Mawad H, Friedler RM, Gao P,Cantor TL, Malluche HH. Improved assessment of bone turnover by the PTH-(1-84)/largeC-PTH fragments ratio in ESRD patients. Kidney Int 2001;60:1460-1468
33. Silverberg S, Gao P, Brown I, LoGer fo P, Cantor T, Bilezikian J. Clinical utility of immunoradiometric assay for parat hyroid hormone (1-84) in primary hyper parat hyroidism. J Clin Endocrinol Metab 2003;88:4725-4730
34. Carnevale V, Dionisi S, Nofroni I, Romagno li E, Paglia F, De Geronimo S, et al. Potential utility of a new IRMA for parat hyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem 2004;50:626-631
35. Boudou P, Ibrahim F, Cormier C, Chabas A, Sarfati E, Souberbielle JC. Third-or second generation Parat hyroid Hormoneas says: A remaining debate in the diagnosis of primary hyper parat hyroidism. J Clin Endocrinol Metab 2005; 90:6370-6372
36. Martin KJ, Jüppner H, Sherra rd DJ, Goodman WG, Kaplan MR, Nassar G, et al. First- and second generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 2005;68:1236-1243
37. Salusky IB, Goodman WG, Kuizon BD, Lavig ne JR, Zahradnik RJ, Gaues S, et al. Similar predictive value of bone turnover using first-and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003;63:1801-1808
38. K/DOQI guidelines for the management of renal osteodystrophy. Am J Kidney Dis 2003;42(suppl 3):S1-5201.
39. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, et al. Aplastic osteodystrophy without aluminum: the role of'suppressed' parat hyroid function. Kidney Int 1993;44:860-866
40. Nussbaum S, Zahradnik R, Lavig ne J, Brennan GL, Nozawa-Ung K, Kim LY, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987;33: 1364-1367
41. Souberbielle JC, Boutten A, Carlier MC, Chevenne D, Coumaros G, Lawson-Body E, et al. Working group on PTH and vitamin D, Societe Francaise de Biologie Clinique(SFBC). Inter-method variability in PTH measurement: Implication for the care of the CKD patients. Kidney Int 2006;70:345-350
42. Malluche HH, Monier-Faugere MC. Understanding andmanaging hyperphos phatemia in patients wi th chronicrenal disease. Clin Nephrol 1999;52:267-277
43. KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention and treatment of chronic kidney disease bone and mineral disorder. Kidney Int 2009;76:S22-S32
44. Melamed ML, Eustace JA, Plantinga LC, Jaar BG, Fink NE, Parekh RS, et al. Third generation parat hyroid hormone assay and all-cause mortality inincident dialysis patients: The CHOICE study. Nephrol Dial Transplant 2007;23:1650-1658
45. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P. Synthetic carboxyl terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from PTH/ PTH-related peptide receptor. Endocrinology 2001;142: 1386-1392
46. Inomata N, Akiyama M, KubotaN, Yuppner H. Characterization of anovel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology 1995;136:4732-4740
47. D'Amour P, Palardy J, Bashali G, Mallette Le, DeLean A, Lepage R. The modulation of circulating parathyroid hormone immunoheterogeneity inman by ionized calcium concentration. J Clin Endocrinol Metab 1992;74:525-532
48. D'Amour P, Rakel A, Brossard JH, Rousseau L, Albert C, Cantor T. Acuteregulation of circulating pa rathyroid hormone (PTH) molecular forms by calcium: Utility of PTH fragments/PTH (1-84) ratiosde rivedfrom three generations of PTH assays. J Clin Endocrinol Metab 2006;91:283-289
49. Souberbielle JCP, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int 2010;77: 93-100.